{{Rsnum
|rsid=10264272
|Gene=CYP3A5
|Chromosome=7
|position=99665212
|Orientation=plus
|ReferenceAllele=G
|GMAF=0.045
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CYP3A5,ZSCAN25
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 100.0 | 0.0 | 0.0
| HCB | 99.3 | 0.7 | 0.0
| JPT | 99.1 | 0.9 | 0.0
| YRI | 70.1 | 26.5 | 3.4
| ASW | 84.2 | 15.8 | 0.0
| CHB | 99.3 | 0.7 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 56.0 | 35.8 | 8.3
| MEX | 94.8 | 5.2 | 0.0
| MKK | 73.1 | 25.0 | 1.9
| TSI | 99.0 | 1.0 | 0.0
| HapMapRevision=28
}}
[[rs10264272]], also known as 14690G>A, is a SNP in the [[CYP3A5]] gene.

{{PMID|21806386}} indicates that this corresponds with CYP3A5*6, however, this seems doubtful.  CYP3A5 allele nomenclature found at http://www.cypalleles.ki.se/cyp3a5.htm indicates that CYP3A5*6 (also known as 14690G>A) is a splicing defect resulting in essentially no activity in the gene.  This does not correspond with dbSNP, which indicates that  is a nucleotide substition (624G-A) which only results in a "silent" substitution of AAG (Lysine) to AAA (Lysine).

{{PharmGKB
|RSID=rs10264272
|Name_s=CYP3A5*6; CYP3A5:711G>A; CYP3A5:Lys208Lys
|Gene_s=CYP3A5, CYP3A
|Feature=Exon/Syn, NA
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/cyp3a5/variant.jsp
|Annotation=Nonfunctional allele present predominantly in the African American population.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161145176
}}

{{PMID Auto
|PMID=21806386
|Title=Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients
}}

{{PMID Auto
|PMID=18341681
|Title=Graft rejection: pharmacogenetic analysis or drug anamnesis?
|OA=1
}}

{{PMID Auto
|PMID=18825162
|Title=Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.
|OA=1
}}

{{PMID Auto
|PMID=20354687
|Title=Explaining variability in ciclosporin exposure in adult kidney transplant recipients.
|OA=1
}}

{{PMID Auto
|PMID=20459744
|Title=Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.
|OA=1
}}

{{PMID Auto
|PMID=24427273
|Title=Global Pharmacogenomics: Distribution of CYP3A5 Polymorphisms and Phenotypes in the Brazilian Population
|OA=1
}}

{{PMID Auto
|PMID=23133420
|Title=Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}